CHF 1.5 million pre-series A funding for Oncobit

Incorporated in 2018, Oncobit has developed a scalable and data-driven cancer monitoring platform based on the quantitative and sensitive detection of cancer markers in liquid biopsies. By focusing on specific cancer markers that are most relevant, Oncobit provides a cost-effective and time-efficient solution for a tight monitoring of the patient’s cancer and optimized therapy management. The company’s cloud-based data analysis and interpretation software was trained in healthy and patient data and ensures a robust and standardized reporting of results. With an initial emphasis on melanoma (already regulatory approved under IVDR certified), Oncobit has generated significant traction, including initial commercial contracts in the pharmaceutical and hospital sectors.

The company has now secured a pre-series A round of CHF 1.5 million with new and existing investors, demonstrating strong confidence in Oncobit's innovative vision and long-term growth potential in the rapidly developing market of liquid biopsy-based cancer monitoring. This will enable the company to generate further clinical data in the melanoma field, expand the monitoring platform to colorectal cancer, and enter additional partnerships and markets including the US. The new investment will also provide the company with the resources needed to continue its rapid growth and further solidify its position in the cancer monitoring market.

"We are incredibly grateful to our existing investors for their unwavering support and to our new investors for joining us on this exciting journey. This round of funding will enable us to invest in key product developments, accelerate our growth plans, and continue delivering value to our customers. The commitment shown by our investors is a testament to the trust they have in our ability to drive innovation in the cancer monitoring space and execute on our vision of enabling personalized cancer care." says Dr. Claudia Scheckel, CEO and Co-Founder of Oncobit.

Bram Goorden, a seasoned diagnostic executive and CEO of IXICO plc, who recently joined the Oncobit’s Board, said “This new capital injection from both existing and new investors is a clear validation for Oncobit’s technology and the impact it has on patients worldwide. It allows Claudia and her team to further accelerate US and European expansion of the platform in precision monitoring of melanoma and other cancer indications, and it sets the company up for a successful Series A round to fuel global commercialization”.

(Press release/RAN)